NCM · Biotechnology

FBRX (FBRX) Stock

$76.57 +0.08% NCM: FBRX Healthcare

Valuation

MetricValue
Price$76.57
Market Cap$1.57B
P/E Ratio-4.26
P/B Ratio4.57
P/S Ratio0.00
EPS (TTM)$-4.71
52-Week High$76.57
52-Week Low$9.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-113.11%
ROA-83.13%
ROCE-116.39%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio3.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-21.0M$-14.0M$-32.0M$-37.0M$-71.0M
Net Profit$-22.0M$-14.0M$-31.0M$-35.0M$-69.0M
EPS$-38.85$-19.96$-24.92$-12.17$-4.71
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$43.0M$42.0M$39.0M$62.0M$83.0M
Total Liabilities$2.0M$3.0M$4.0M$9.0M$22.0M
Cash$42.0M$41.0M$12.0M$22.0M$77.0M
Borrowings$0$0$0$0$0

Latest News

TRAX Stock Hits All-Time High — What's Driving The Super Rally? Stocktwits · Jul 10, 2026 FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data Zacks · Jul 10, 2026 Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement MarketBeat · Jul 10, 2026 Top Midday Gainers MT Newswires · Jul 9, 2026 Forte Biosciences shares surge after positive phase 1b vitiligo results Proactive · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-17.0M$-8.0M$-29.0M$-31.0M$-51.0M
Investing Cash Flow$0$0$0$-36.0M$36.0M
Financing Cash Flow$0$0$0$-1.0M$-7.0M
Net Cash Flow$-17.0M$-1.0M$-4.0M$-15.0M$55.0M
Free Cash Flow$-17.0M$-8.0M$-29.0M$-31.0M$-51.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-20.93%
Quick Ratio2.75
Interest Coverage—
Return 1Y461.09%
Return 3Y136.44%
Return 5Y-94.39%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACTU $1.09 -5.22% -2.73 $26.08M 0.00%
ALEC $1.52 +0.33% -1.58 $168.20M 0.00%
APLTApplied Therapeutics, Inc. $0.10 +0.00% -0.24 $14.86M 0.00%
CRBP $9.11 +0.33% -1.95 $168.79M 0.00%
CRDF $0.81 -2.98% -2.58 $53.22M 0.00%

About FBRX

FBRX is led by CEO Paul A. Wagner, employs 14 people, headquartered in US, publicly traded since 2017.

FBRX stock trades at $76.57 with a market capitalization of $1.57B. The stock is valued at a price-to-earnings (P/E) ratio of -4.26, price-to-book of 4.57, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $9.10 and $76.57, and currently trades at its 52-week high.

On profitability, FBRX generates a return on equity (ROE) of -113.11%, return on capital employed of -116.39%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides